Title:
MUTANT CALR-PEPTIDE BASED VACCINE
Document Type and Number:
WIPO Patent Application WO/2023/245139
Kind Code:
A3
Abstract:
The presently claimed and described technology provides vaccine compositions comprising at least two mutant-calreticulin (CALR)-peptides, wherein the at least two peptides have overlapping sequences and methods for administration of the vaccine compositions to induce or elicit an antitumor response or improve or enhance antitumor T cell immunity and methods of preventing, treating, reducing, or slowing progression or development of a hematological malignancy in a subject with a calreticulin mutation.
More Like This:
| JP2008263997 | DENDRITIC CELL HYBRID |
| JP2013526582 | Cancer treatment |
| JP2009131272 | RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION |
Inventors:
BHARDWAJ NINA (US)
IANCU-RUBIN CAMELIA (US)
HOFFMAN RONALD (US)
CIMEN BOZKUS CANSU (US)
IANCU-RUBIN CAMELIA (US)
HOFFMAN RONALD (US)
CIMEN BOZKUS CANSU (US)
Application Number:
PCT/US2023/068539
Publication Date:
February 08, 2024
Filing Date:
June 15, 2023
Export Citation:
Assignee:
ICAHN SCHOOL MED MOUNT SINAI (US)
International Classes:
A61K39/00; A61K9/00; A61K39/385; A61K39/39; A61P7/00; A61P35/02; A61P37/04
Foreign References:
| US20190328857A1 | 2019-10-31 | |||
| US20200040399A1 | 2020-02-06 | |||
| US20220024944A1 | 2022-01-27 |
Attorney, Agent or Firm:
TYSON, Malaika O. (US)
Download PDF: